BACKGROUND: To elucidate the differences in chemosensitivity to anticancer drugs between primary and metastatic lesions in non-small cell lung cancer (NSCLC) patients, we examined the in vitro chemosensitivities of surgically resected NSCLC tissues. METHODS: A total of 32 specimens were enrolled: 26 specimens of primary lesions paired with metastases in the lymph node, 3 specimens of primary lesions paired with metastases in the adrenal gland, and 3 specimens of primary lesions paired with metastases in the lung. The collagen gel droplet embedded culture drug test (CD-DST) was applied to examine the sensitivity of the tissues to anticancer drugs, including cisplatin, gemcitabine, vinorelbine, docetaxel and 5-fluorouracil. RESULTS: The degree of in vitro sensitivity to each anticancer drug varied between the primary and metastatic lesions. The sensitivity of the paired metastatic lesions was significantly lower than that of the primary lesions only for gemcitabine (P=0.029), vinorelbine (P=0.012), and docetaxel (P=0.009). The incidence of cases diagnosed as CD-DST-sensitive among the paired metastatic lesions was significantly lower than that for the primary lesions for vinorelbine (P=0.035) or docetaxel (P=0.022). The difference in the sensitivity to gemcitabine between the primary and paired non-lymphatic metastases was clearer than that between the primary lesion and paired lymph node metastases. CONCLUSIONS: The sensitivities of the paired metastatic lesions to some anticancer drugs were significantly lower than those of the primary lesions. When performing chemotherapy based on CD-DST data using primary tumors from patients with postoperative recurrence, an appropriate regimen can be selected by carefully considering these differences.
BACKGROUND: To elucidate the differences in chemosensitivity to anticancer drugs between primary and metastatic lesions in non-small cell lung cancer (NSCLC) patients, we examined the in vitro chemosensitivities of surgically resected NSCLC tissues. METHODS: A total of 32 specimens were enrolled: 26 specimens of primary lesions paired with metastases in the lymph node, 3 specimens of primary lesions paired with metastases in the adrenal gland, and 3 specimens of primary lesions paired with metastases in the lung. The collagen gel droplet embedded culture drug test (CD-DST) was applied to examine the sensitivity of the tissues to anticancer drugs, including cisplatin, gemcitabine, vinorelbine, docetaxel and 5-fluorouracil. RESULTS: The degree of in vitro sensitivity to each anticancer drug varied between the primary and metastatic lesions. The sensitivity of the paired metastatic lesions was significantly lower than that of the primary lesions only for gemcitabine (P=0.029), vinorelbine (P=0.012), and docetaxel (P=0.009). The incidence of cases diagnosed as CD-DST-sensitive among the paired metastatic lesions was significantly lower than that for the primary lesions for vinorelbine (P=0.035) or docetaxel (P=0.022). The difference in the sensitivity to gemcitabine between the primary and paired non-lymphatic metastases was clearer than that between the primary lesion and paired lymph node metastases. CONCLUSIONS: The sensitivities of the paired metastatic lesions to some anticancer drugs were significantly lower than those of the primary lesions. When performing chemotherapy based on CD-DST data using primary tumors from patients with postoperative recurrence, an appropriate regimen can be selected by carefully considering these differences.
Entities:
Keywords:
Non-small cell lung cancer (NSCLC); chemosensitivity test; chemotherapy; collagen gel droplet embedded culture drug test (CD-DST); metastatic tissue
Authors: G L Shaw; A F Gazdar; R Phelps; S M Steinberg; R I Linnoila; B E Johnson; H K Oie; E K Russell; B C Ghosh; H I Pass; J D Minna; J L Mulshine; D C Ihde Journal: J Cell Biochem Suppl Date: 1996
Authors: Sharon Glaysher; Dennis Yiannakis; Francis G Gabriel; Penny Johnson; Marta E Polak; Louise A Knight; Zoe Goldthorpe; Katharine Peregrin; Mya Gyi; Paul Modi; Joe Rahamim; Mark E Smith; Khalid Amer; Bruce Addis; Matthew Poole; Ajit Narayanan; Tim J Gulliford; Peter E Andreotti; Ian A Cree Journal: BMC Cancer Date: 2009-08-27 Impact factor: 4.430
Authors: Xi Tian; Michael E Werner; Kyle C Roche; Ariel D Hanson; Henry P Foote; Stephanie K Yu; Samuel B Warner; Jonathan A Copp; Haydee Lara; Eliane L Wauthier; Joseph M Caster; Laura E Herring; Longzhen Zhang; Joel E Tepper; David S Hsu; Tian Zhang; Lola M Reid; Andrew Z Wang Journal: Nat Biomed Eng Date: 2018-04-23 Impact factor: 25.671
Authors: Meredith C Mason; Maciej Krasnodebski; Caitlin A Hester; Anai N Kothari; Caeli Barker; Yujiro Nishioka; Yi-Ju Chiang; Timothy E Newhook; Ching-Wei D Tzeng; Yun Shin Chun; Jean-Nicolas Vauthey; Hop S Tran Cao Journal: Ann Surg Oncol Date: 2022-04-10 Impact factor: 5.344